fesoterodine fumarate (Toviaz)

Advice

Following a full submission

fesoterodine fumarate prolonged release tablets (Toviaz®) are accepted for restricted use within NHS Scotland for treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur in patients with overactive bladder syndrome.

Fesoterodine is effective in reducing symptoms associated with overactive bladder syndrome without a neurological cause and was of equivalent efficacy to a comparator antimuscarinic agent in one study.

Fesoterodine is associated with adverse effects typical of antimuscarinic agents used in this condition. It is restricted to second-line use as there are cheaper antimuscarinics available that would normally be used as first-line agents.